---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-22-000026"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:41:51.839559+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex Q2 product revenue $2.20B (+22% YoY); raises FY2022 guidance to $8.6-$8.8B

## Summary
- Product revenues $2.20B, up 22% YoY; TRIKAFTA/KAFTRIO contributed $1.893B.
- GAAP diluted EPS $3.13; non-GAAP diluted EPS $3.60.
- Raised full-year 2022 product revenue guidance to $8.6-$8.8B from prior $8.4-$8.6B.
- Clinical updates: exa-cel (sickle cell/beta thalassemia) and VX-880 (type 1 diabetes) data demonstrate transformative potential.

## SEC filing metadata
- accession: 0000875320-22-000026
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532022000026/0000875320-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532022000026/vrtx-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-22-000026
- JSON: https://secwatch.observer/filing/0000875320-22-000026.json
- Plain text: https://secwatch.observer/filing/0000875320-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.